United States - English - NLM (National Library of Medicine)

allure labs, inc - zinc oxide (unii: soi2loh54z) (zinc cation - unii:13s1s8sf37), titanium dioxide (unii: 15fix9v2jp) (titanium dioxide - unii:15fix9v2jp) - zinc cation 85.0 mg in 1 ml - sunscreen uses: helps prevent sunburn. if used as directed with other sun protection measures, decreases the rsk of skin cancer and early skin aging caused by the sun. post treatment camouflage for skin needling and rejuvenation procedures.

United States - English - NLM (National Library of Medicine)

allure labs, inc - zinc oxide (unii: soi2loh54z) (zinc cation - unii:13s1s8sf37), titanium dioxide (unii: 15fix9v2jp) (titanium dioxide - unii:15fix9v2jp) - zinc cation 85.0 mg in 1 ml - sunscreen uses: helps prevent sunburn. if used as directed with other sun protection measures, decreases the rsk of skin cancer and early skin aging caused by the sun. post treatment camouflage for skin needling and rejuvenation procedures.

European Union - English - EMA (European Medicines Agency)

glaxosmithkline (ireland) limited - umeclidinium bromide - pulmonary disease, chronic obstructive - drugs for obstructive airway diseases, - indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (copd).,

Philippines - English - FDA (Food And Drug Administration)

euro-med labs inc. - 5% dextrose in 0.9% sodium chloride - solution for intravenous infusion

Philippines - English - FDA (Food And Drug Administration)

euro-med labs inc. - ambroxol hydrochloride - syrup - 30mg/5 ml

Philippines - English - FDA (Food And Drug Administration)

euro-med labs inc - paracetamol - tablet - 500mg

Philippines - English - FDA (Food And Drug Administration)

euro-med labs inc - povidone-iodine - solution (feminine wash) - 0.07

Philippines - English - FDA (Food And Drug Administration)

euro-med labs inc. - sodium chloride - solution for inhalation - 0.9%

Philippines - English - FDA (Food And Drug Administration)

euro-med labs inc. - terbutaline sulfate - solution for injection im/iv - 0.0005

European Union - English - EMA (European Medicines Agency)

sun pharmaceutical industries europe b.v. - docetaxel - stomach neoplasms; adenoma; breast neoplasms; carcinoma, non-small-cell lung; prostatic neoplasms - antineoplastic agents - breast cancerdocetaxel in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node-positive breast cancer.docetaxel in combination with doxorubicin is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have not previously received cytotoxic therapy for this condition.docetaxel monotherapy is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic therapy. previous chemotherapy should have included an anthracycline or an alkylating agent.docetaxel in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumours over express her2 and who previously have not received chemotherapy for metastatic disease.docetaxel in combination with capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy. previous therapy should have included an anthracycline.non-small cell lung cancerdocetaxel is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior chemotherapy.docetaxel in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small cell lung cancer, in patients who have not previously received chemotherapy for this condition.prostate cancerdocetaxel in combination with prednisone or prednisolone is indicated for the treatment of patients with hormone refractory metastatic prostate cancer.gastric adenocarcinomadocetaxel in combination with cisplatin and 5-fluorouracil is indicated for the treatment of patients with metastatic gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction, who have not received prior chemotherapy for metastatic disease.head and neck cancerdocetaxel in combination with cisplatin and 5-fluorouracil is indicated for the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck.